Clinitech Laboratory IPO Listed at ₹115 with 20% Premium

Clinitech Laboratory experienced an outstanding debut on the market today, with its shares listed at ₹115 each on BSE SME, marking a 20% premium over the issue price of ₹96. This SME IPO, which was valued at ₹5.78 crore, was open for subscription from July 25 to July 29, 2024, priced at ₹96 per share.

The IPO included solely a fresh issuance of 6.02 lakh new shares, without any offer-for-sale portion. It received a robust response, achieving an overall subscription rate of 38.96 times. Retail investors were particularly enthusiastic, subscribing 49.91 times, while non-retail segments also showed strong interest with a subscription rate of 23.28 times.

Clinitech Laboratory is a prominent provider of diagnostic and healthcare testing services through its network of eight diagnostic centers in and around Thane and Navi Mumbai. The company boasts 30 years of experience in the diagnostic industry.

Annually, its facilities perform over 300,000 tests using advanced technology and high-end equipment in their NABL-accredited (National Accreditation Board for Testing and Calibration Laboratories) labs. The centers offer a comprehensive array of more than 150 tests, spanning various categories such as biochemistry, immunology, hematology, molecular biology, serology, microbiology, and histopathology.

Additionally, the company has earned a Certificate of Accreditation from NABL in accordance with ISO 15189:2012 for its medical testing facilities in Airoli, Navi Mumbai. This certification enables the company to uphold the quality of its services.

To Summarize

Clinitech Laboratory experienced an outstanding debut on the market today, with its shares listed at ₹115 each on BSE SME, marking a 20% premium over the issue price of ₹96. This SME IPO, which was valued at ₹5.78 crore, was open for subscription from July 25 to July 29, 2024, priced at ₹96 per share. The IPO included solely a fresh issuance of 6.02 lakh new shares, without any offer-for-sale portion. It received a robust response, achieving an overall subscription rate of 38.96 times.